ID1 is a transcription factor that plays a critical role in the initiation and progression of melanoma, a particularly aggressive form of skin cancer. By conjugating anti-ID1 antibodies to liposomes, researchers have developed a novel strategy that enables the precise targeting of malignant cells, thereby enhancing the delivery of therapeutic agents directly to the tumor site. This targeted approach has the potential to not only inhibit tumor growth but also to reduce the risk of metastasis, offering a more effective treatment option for patients battling this challenging disease.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-772LC | Anti-human ITGB1 Recombinant Antibody (1B4) (TAB-772LC) | FuncS | |
TAB-772LC-S(P) | Anti-human ITGB1 scFv Fragment (1B4) | ELISA | |
TAB-772LC-F(E) | Anti-human ITGB1 Fab Fragment (1B4) | ELISA |
There are currently no Customer reviews or questions for VS-1024-FY186. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.